Who is sponsoring NCT05500157?

NCT05500157 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT05500157?

Interventions in NCT05500157: aspiration sclerotherapy versus laparoscopic fenestration.

What condition does NCT05500157 study?

NCT05500157 studies Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease.

Is NCT05500157 still recruiting?

NCT05500157 is currently status unknown. Last updated 5 April 2023.

Last reviewed 2023-04-05 · How we verify

NCT05500157: ATLAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts

Status unknown NA Last updated 5 April 2023

What this trial tests

NA trial testing aspiration sclerotherapy versus laparoscopic fenestration in Liver Cyst in 70 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
1 October 2023

1 October 2024

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 October 2022
Primary completion	1 October 2023
Estimated completion	1 October 2024
Sites	1 location across Netherlands

Drugs / interventions tested

aspiration sclerotherapy versus laparoscopic fenestration

Conditions studied

Liver Cyst — all drugs for Liver Cyst →
Polycystic Liver Disease — all drugs for Polycystic Liver Disease →
Autosomal Dominant Polycystic Kidney — all drugs for Autosomal Dominant Polycystic Kidney →
Autosomal Dominant Polycystic Liver Disease — all drugs for Autosomal Dominant Polycystic Liver Disease →

Sponsor

Radboud University Medical Center

Who can join

Adults 18 to 75, any sex, with Liver Cyst or Polycystic Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with large hepatic cysts (\> 5cm) may develop symptoms. These can be captured with the polycystic liver disease questionnaire (PLD-Q). Treatment of large hepatic cysts consists of aspiration sclerotherapy or laparoscopic fenestration. The safety and efficacy of both procedures has been explored in two recent systematic reviews yet no evident conclusion regarding superiority of either procedure could be drawn. The main objective of the ATLAS trial is to compare laparoscopic fenestration and aspiration sclerotherapy in patients with large symptomatic hepatic cysts on patient-reported outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
Mahboobipour AA, Ala M, Safdari Lord J, Yaghoobi A. · · 2024 · cited 7× · PMID 38671465 · DOI 10.1186/s13023-024-03187-w

Verify or expand the search:

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05500157 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 5 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05500157.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing